These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30062091)

  • 1. Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment.
    Shrestha R; Copenhaver M
    Front Public Health; 2018; 6():195. PubMed ID: 30062091
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study.
    Shrestha R; Altice FL; Karki P; Copenhaver MM
    AIDS Behav; 2018 Aug; 22(8):2640-2649. PubMed ID: 29582199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives.
    Surratt HL; Yeager HJ; Adu A; González EA; Nelson EO; Walker T
    Front Psychiatry; 2022; 13():905314. PubMed ID: 35706473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
    Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
    Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment.
    Shrestha R; Karki P; Altice FL; Huedo-Medina TB; Meyer JP; Madden L; Copenhaver M
    Drug Alcohol Depend; 2017 Apr; 173():107-116. PubMed ID: 28214391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya.
    Patel RC; Stanford-Moore G; Odoyo J; Pyra M; Wakhungu I; Anand K; Bukusi EA; Baeten JM; Brown JM
    J Int AIDS Soc; 2016; 19(1):21134. PubMed ID: 27964776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Online HIV information seeking and pre-exposure prophylaxis awareness among people who use drugs.
    Ranjit YS; Shrestha R; Copenhaver M; Altice FL
    J Subst Abuse Treat; 2020 Apr; 111():16-22. PubMed ID: 32087834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis.
    Shrestha R; Altice FL; DiDomizio E; Sibilio B; Ranjit YS; Copenhaver MM
    Patient Prefer Adherence; 2020; 14():107-118. PubMed ID: 32021122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV.
    Gombe MM; Cakouros BE; Ncube G; Zwangobani N; Mareke P; Mkwamba A; Prescott MR; Bhatasara T; Murwira M; Mangwiro AZ; Prust ML
    PLoS One; 2020; 15(1):e0227632. PubMed ID: 31931514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study.
    Closson EF; Mitty JA; Malone J; Mayer KH; Mimiaga MJ
    AIDS Care; 2018 Feb; 30(2):191-198. PubMed ID: 28830220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Hershow RB; Gonzalez M; Costenbader E; Zule W; Golin C; Brinkley-Rubinstein L
    AIDS Educ Prev; 2019 Aug; 31(4):363-379. PubMed ID: 31361517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Young Transgender Women's Attitudes Toward HIV Pre-exposure Prophylaxis.
    Wood SM; Lee S; Barg FK; Castillo M; Dowshen N
    J Adolesc Health; 2017 May; 60(5):549-555. PubMed ID: 28132744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Capacity-Strengthening Intervention for Frontline Harm Reduction Workers to Support Pre-exposure Prophylaxis Awareness-Building and Promotion Among People Who Use Drugs: Formative Research and Intervention Development.
    Glick JL; Zhang L; Rosen JG; Yaroshevich K; Atiba B; Pelaez D; Park JN
    JMIR Form Res; 2023 Apr; 7():e42418. PubMed ID: 37052977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation.
    Chakrapani V; Newman PA; Shunmugam M; Mengle S; Varghese J; Nelson R; Bharat S
    AIDS Patient Care STDS; 2015 Oct; 29(10):569-77. PubMed ID: 26348459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis.
    Shrestha R; Karki P; Huedo-Medina TB; Copenhaver M
    J Assoc Nurses AIDS Care; 2017; 28(4):612-621. PubMed ID: 28478870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study.
    Storholm ED; Volk JE; Marcus JL; Silverberg MJ; Satre DD
    Prev Sci; 2017 Aug; 18(6):737-747. PubMed ID: 28578516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Bazzi AR; Biancarelli DL; Childs E; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Biello KB
    AIDS Patient Care STDS; 2018 Dec; 32(12):529-537. PubMed ID: 30311777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review.
    Pacífico de Carvalho N; Mendicino CCP; Cândido RCF; Alecrim DJD; Menezes de Pádua CA
    AIDS Care; 2019 Oct; 31(10):1234-1240. PubMed ID: 31043069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing the Effectiveness and Cost-Effectiveness of a Combination HIV Prevention Intervention Among Young Cisgender Men Who Have Sex With Men and Transgender Women Who Sell or Exchange Sex in Thailand: Protocol for the Combination Prevention Effectiveness Study.
    Wirtz AL; Weir BW; Mon SHH; Sirivongrangson P; Chemnasiri T; Dunne EF; Varangrat A; Hickey AC; Decker MR; Baral S; Okanurak K; Sullivan P; Valencia R; Thigpen MC; Holtz TH; Mock PA; Cadwell B; Adeyeye A; Rooney JF; Beyrer C;
    JMIR Res Protoc; 2020 Jan; 9(1):e15354. PubMed ID: 32012113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.